Vir Biotechnology Signs $1.875 Billion Gilead Oncology Collaboration

Key numbers

Deal value	$1.9B
Share of market cap	104.4%
Share of annual revenue	2818.7%

Key highlights

• Total deal value reaches $1.875 billion including upfront and potential milestone payments
• Upfront consideration of $90 million includes $65 million in cash and $25 million in equity
• Gilead purchased 1,765,486 shares at $14.16 each, a 30% premium over market price
• Collaboration focuses on three novel PRO-XTEN dual-masked T-cell engager candidates
• Vir is eligible for tiered high single-digit to low double-digit royalties on net sales

Terms of the Strategic Collaboration

Vir Biotechnology and Gilead Sciences have established a global strategic partnership to discover and engineer three novel PRO-XTEN dual-masked T-cell engager (TCE) candidates for solid tumors. Vir receives $90 million in upfront consideration, comprised of $65 million in cash and a $25 million equity investment at a 30% premium. The agreement outlines up to $45 million in near-term preclinical milestones and $1.74 billion in future development, regulatory, and commercial milestones. Gilead receives an exclusive license to develop and commercialize the resulting candidates, while Vir Biotechnology remains eligible for tiered high single-digit to low double-digit royalties on eventual net sales.

Strategic Significance and Technology Platform

• Utilization of the dAIsY AI platform for rapid, multiparameter optimization of high-quality T-cell engagers
• Integration of the universal PRO-XTEN masking technology to enhance therapeutic index across solid tumor targets
• Expansion of Vir's oncology footprint through external validation from a major pharmaceutical developer
• Projected extension of cash runway into the second half of 2028 based on new capital inflows
• Diversification of the clinical pipeline beyond existing infectious disease and chronic hepatitis delta programs

Management Perspective

“We believe TCEs have a powerful role to play in the future of immunotherapy to treat cancer. This collaboration with Gilead provides an opportunity to generate multiple differentiated candidates aimed at difficult-to-address solid tumors and to expand the potential impact of our science, while also advancing our own clinical oncology portfolio.”

Business and Financial Landscape

Vir Biotechnology operates as a clinical-stage biopharmaceutical firm focusing on immune system therapies for infectious diseases and cancer. The Gilead deal follows a 2026 collaboration with Astellas for the VIR-5500 program, which recently received FDA Fast Track designation for metastatic prostate cancer. With a market capitalization of $1.8 billion, Vir continues to leverage its protein engineering expertise and AI-enabled platforms to secure non-dilutive funding. The company is currently preparing for critical clinical milestones, including the topline Phase 3 ECLIPSE 1 trial data for chronic hepatitis delta expected in the fourth quarter of 2026.

Down 1.4% over the last month ($10.77 on 14 Sep → $10.61 on 13 Oct). Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$10.77
15 Sep	$10.44
16 Sep	$10.52
17 Sep	$10.92
18 Sep	$10.60
21 Sep	$10.88
22 Sep	$11.50
23 Sep	$11.09
24 Sep	$10.72
25 Sep	$10.66
28 Sep	$10.51
29 Sep	$10.65
30 Sep	$11.18
1 Oct	$11.29
2 Oct	$11.17
5 Oct	$11.78
6 Oct	$11.60
7 Oct	$11.52
8 Oct	$11.12
9 Oct	$11.70
12 Oct	$11.30
13 Oct	$10.61

Management commentary

“Together with Vir Biotechnology, we seek to bring meaningful innovative therapeutics to patients.”

Vir Biotechnology, Inc. · financial snapshot

Share price	$10.61
Market cap	$1.8B
Revenue (annual)	$67M
1-month price change	-0.09%
Sector	HealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.